JP2021525731A5 - - Google Patents
Info
- Publication number
- JP2021525731A5 JP2021525731A5 JP2020566664A JP2020566664A JP2021525731A5 JP 2021525731 A5 JP2021525731 A5 JP 2021525731A5 JP 2020566664 A JP2020566664 A JP 2020566664A JP 2020566664 A JP2020566664 A JP 2020566664A JP 2021525731 A5 JP2021525731 A5 JP 2021525731A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- amino acid
- acid sequence
- variable domain
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023201568A JP7726967B2 (ja) | 2018-05-28 | 2023-11-29 | 多重特異性結合タンパク質及びその改善 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862677137P | 2018-05-28 | 2018-05-28 | |
| US62/677,137 | 2018-05-28 | ||
| PCT/US2019/034186 WO2019231920A1 (en) | 2018-05-28 | 2019-05-28 | Multi-specific binding proteins and improvements thereon |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023201568A Division JP7726967B2 (ja) | 2018-05-28 | 2023-11-29 | 多重特異性結合タンパク質及びその改善 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525731A JP2021525731A (ja) | 2021-09-27 |
| JPWO2019231920A5 JPWO2019231920A5 (https=) | 2022-06-07 |
| JP2021525731A5 true JP2021525731A5 (https=) | 2022-06-07 |
Family
ID=68697331
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566664A Pending JP2021525731A (ja) | 2018-05-28 | 2019-05-28 | 多重特異性結合タンパク質及びその改善 |
| JP2023201568A Active JP7726967B2 (ja) | 2018-05-28 | 2023-11-29 | 多重特異性結合タンパク質及びその改善 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023201568A Active JP7726967B2 (ja) | 2018-05-28 | 2023-11-29 | 多重特異性結合タンパク質及びその改善 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210214436A1 (https=) |
| EP (2) | EP3802581A4 (https=) |
| JP (2) | JP2021525731A (https=) |
| KR (1) | KR20210013160A (https=) |
| CN (2) | CN117964773A (https=) |
| AU (1) | AU2019277138B2 (https=) |
| BR (1) | BR112020024235A2 (https=) |
| CA (1) | CA3101604A1 (https=) |
| CL (1) | CL2020003071A1 (https=) |
| EA (2) | EA202091977A1 (https=) |
| IL (1) | IL278943A (https=) |
| MX (1) | MX2020012905A (https=) |
| PE (1) | PE20210167A1 (https=) |
| SG (1) | SG11202011763YA (https=) |
| WO (1) | WO2019231920A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018510627A (ja) * | 2015-03-10 | 2018-04-19 | レイデン ユニバーシティ メディカル センター | メラノーマ優先発現抗原に対して向けられたｔ細胞レセプターおよびその使用 |
| HUE058957T2 (hu) | 2016-12-08 | 2022-10-28 | Immatics Biotechnologies Gmbh | Új T-sejt receptorok és velük végzett immunterápia |
| SG11201907299XA (en) | 2017-02-08 | 2019-09-27 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| IL268755B2 (en) | 2017-02-20 | 2025-12-01 | Dragonfly Therapeutics Inc | Proteins that bind her2, nkg2d, and cd16 |
| SG11202000025SA (en) | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| EA202091887A1 (ru) | 2018-02-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры |
| DK3749346T3 (da) | 2018-02-08 | 2024-09-09 | Dragonfly Therapeutics Inc | Antistof variable domænekombinationer rettet mod nkg2d-receptoren |
| WO2019164930A1 (en) * | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| MX2021001510A (es) * | 2018-08-08 | 2021-07-02 | Dragonfly Therapeutics Inc | Proteínas de union a nkg2d, cd16, y un antígeno asociado a tumores. |
| WO2020033630A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| US12378318B2 (en) | 2018-08-08 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and a tumor-associated antigen |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| ES2974424T3 (es) * | 2019-01-17 | 2024-06-27 | Immunocore Ltd | Formulaciones |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| EP3962527A4 (en) | 2019-04-30 | 2023-11-01 | Senti Biosciences, Inc. | CHIMERIC RECEPTORS AND METHODS OF USE THEREOF |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| CN116096758A (zh) * | 2020-05-01 | 2023-05-09 | 诺华股份有限公司 | 工程化免疫球蛋白 |
| CN116096754A (zh) * | 2020-05-04 | 2023-05-09 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| CN113754771A (zh) * | 2020-06-02 | 2021-12-07 | 三生国健药业（上海）股份有限公司 | 一种抗pdl1×egfr的双特异性抗体 |
| JP2023545099A (ja) * | 2020-10-08 | 2023-10-26 | アフィメド ゲーエムベーハー | 三重特異性バインダー |
| EP4273161A4 (en) * | 2020-12-31 | 2025-04-02 | Innovent Biologics (Suzhou) Co., Ltd. | Protein with heterodimeric antibody FC and manufacturing method therefor |
| AU2022206475A1 (en) * | 2021-01-11 | 2023-08-17 | Adimab, Llc | Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof |
| JP2024508894A (ja) | 2021-03-03 | 2024-02-28 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法 |
| IL307312A (en) * | 2021-03-31 | 2023-11-01 | Janssen Biotech Inc | Materials and methods for redirecting immune effector cells |
| EP4334361A1 (en) | 2021-05-05 | 2024-03-13 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
| EP4405398A4 (en) * | 2021-09-21 | 2025-10-29 | Qilu Puget Sound Biotherapeutics Corp | FC HETERODIMERS ALLOWING THE MANUFACTURE OF FUSION PROTEINS AND BI-SPECIFIC ANTIBODIES |
| JP2025501358A (ja) * | 2022-01-05 | 2025-01-17 | 蘇州系統医学研究所 | Ｔ細胞受容体、その製造方法、及び使用 |
| WO2023148494A1 (en) * | 2022-02-03 | 2023-08-10 | University College Cardiff Consultants Limited | Novel t-cell receptor |
| AU2024287954A1 (en) * | 2023-07-07 | 2026-01-22 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Egfr/c-met bispecific binding protein and use thereof |
| WO2025050020A1 (en) * | 2023-08-30 | 2025-03-06 | Mink Therapeutics, Inc. | Novel t cell receptors that bind to preferentially expressed antigen in melanoma (prame) and methods of use thereof |
| WO2025233431A1 (en) * | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof |
| WO2025247255A1 (zh) * | 2024-05-28 | 2025-12-04 | 映恩生物科技(上海)有限公司 | 一种抗dll3抗体、抗体药物偶联物及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10156482A1 (de) * | 2001-11-12 | 2003-05-28 | Gundram Jung | Bispezifisches Antikörper-Molekül |
| AU2005291039A1 (en) * | 2004-10-01 | 2006-04-13 | Avidex Ltd. | T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents |
| GB0614780D0 (en) * | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| KR101615935B1 (ko) | 2007-12-14 | 2016-04-28 | 노보 노르디스크 에이/에스 | 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도 |
| US9273136B2 (en) | 2008-08-04 | 2016-03-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fully human anti-human NKG2D monoclonal antibodies |
| UY32808A (es) | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| LT2794658T (lt) * | 2011-12-19 | 2017-05-10 | Synimmune Gmbh | Bispecifinė antikūno molekulė |
| CN104271602B (zh) * | 2012-11-21 | 2020-08-21 | 武汉友芝友生物制药有限公司 | 双特异性抗体 |
| EP3878964A1 (en) * | 2012-11-27 | 2021-09-15 | Ajou University Industry-Academic Cooperation Foundation | Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof |
| CA2902739C (en) * | 2013-03-15 | 2022-11-22 | Xencor, Inc. | Heterodimeric proteins |
| WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| CN107001482B (zh) * | 2014-12-03 | 2021-06-15 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
| CA2970255A1 (en) * | 2014-12-17 | 2016-06-23 | Intrexon Corporation | Intercalated single-chain variable fragments |
| WO2016115274A1 (en) | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| CN107530424A (zh) | 2015-02-20 | 2018-01-02 | 俄亥俄州国家创新基金会 | 针对nkg2d和肿瘤相关抗原的二价抗体 |
| EP3095792A1 (en) * | 2015-05-19 | 2016-11-23 | Klinikum rechts der Isar der Technischen Universität München | T cell receptor with specificity for myeloperoxidase peptide and uses thereof |
| DK3313876T3 (da) * | 2015-06-23 | 2025-04-22 | Innate Pharma | Multispecifikke antigenbindende proteiner |
| WO2017081190A1 (en) * | 2015-11-13 | 2017-05-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- nkg2d single domain antibodies and uses thereof |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| SG11201907299XA (en) * | 2017-02-08 | 2019-09-27 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| MA47465A (fr) * | 2017-02-10 | 2019-12-18 | Dragonfly Therapeutics Inc | Protéines fixant le bcma, le nkg2d et le cd16 |
| CA3054078A1 (en) * | 2017-02-20 | 2018-08-23 | Dragonfly Therapeutics, Inc. | Proteins binding cd33, nkg2d and cd16 |
| IL268755B2 (en) * | 2017-02-20 | 2025-12-01 | Dragonfly Therapeutics Inc | Proteins that bind her2, nkg2d, and cd16 |
| AU2018318698A1 (en) * | 2017-08-16 | 2020-02-20 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16, and EGFR, HLA-E CCR4, or PD-L1 |
| SG10202102502VA (en) * | 2017-09-07 | 2021-04-29 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| WO2019164930A1 (en) * | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| EP3755348A4 (en) * | 2018-02-20 | 2022-03-02 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting cd33, and use thereof |
-
2019
- 2019-02-20 EA EA202091977A patent/EA202091977A1/ru unknown
- 2019-05-28 EP EP19812582.5A patent/EP3802581A4/en not_active Ceased
- 2019-05-28 EA EA202092907A patent/EA202092907A1/ru unknown
- 2019-05-28 MX MX2020012905A patent/MX2020012905A/es unknown
- 2019-05-28 BR BR112020024235-7A patent/BR112020024235A2/pt unknown
- 2019-05-28 EP EP24215746.9A patent/EP4537904A3/en active Pending
- 2019-05-28 US US17/058,335 patent/US20210214436A1/en active Pending
- 2019-05-28 CN CN202311768455.3A patent/CN117964773A/zh active Pending
- 2019-05-28 SG SG11202011763YA patent/SG11202011763YA/en unknown
- 2019-05-28 KR KR1020207036884A patent/KR20210013160A/ko not_active Ceased
- 2019-05-28 WO PCT/US2019/034186 patent/WO2019231920A1/en not_active Ceased
- 2019-05-28 JP JP2020566664A patent/JP2021525731A/ja active Pending
- 2019-05-28 CN CN201980049197.9A patent/CN112533944A/zh active Pending
- 2019-05-28 CA CA3101604A patent/CA3101604A1/en active Pending
- 2019-05-28 AU AU2019277138A patent/AU2019277138B2/en active Active
- 2019-05-28 PE PE2020001934A patent/PE20210167A1/es unknown
-
2020
- 2020-11-24 IL IL278943A patent/IL278943A/en unknown
- 2020-11-26 CL CL2020003071A patent/CL2020003071A1/es unknown
-
2023
- 2023-11-29 JP JP2023201568A patent/JP7726967B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021525731A5 (https=) | ||
| JPWO2019231920A5 (https=) | ||
| Hosseini et al. | Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: recent advances and clinical trials | |
| Goebeler et al. | Bispecific and multispecific antibodies in oncology: opportunities and challenges | |
| Thakur et al. | Cancer therapy with bispecific antibodies: Clinical experience | |
| JP7487112B2 (ja) | Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用 | |
| Chen et al. | Bispecific antibodies in cancer immunotherapy | |
| Zhang et al. | The development of bispecific antibodies and their applications in tumor immune escape | |
| May et al. | Advances in bispecific biotherapeutics for the treatment of cancer | |
| Weidle et al. | Tumor-antigen–binding bispecific antibodies for cancer treatment | |
| Moon et al. | Development of bispecific antibody for cancer immunotherapy: focus on T cell engaging antibody | |
| JP2017531687A5 (https=) | ||
| US20230028399A1 (en) | Bcma-directed cellular immunotherapy compositions and methods | |
| WO2019005641A1 (en) | GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF | |
| IL319102A (en) | Guidance and navigation control proteins and method for producing and using them | |
| JP2020522473A5 (https=) | ||
| JP2020531525A5 (https=) | ||
| Urbanska et al. | Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells | |
| RU2020111554A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| JP2021514631A5 (https=) | ||
| Satta et al. | Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors | |
| JPWO2019157366A5 (https=) | ||
| Dhimolea et al. | World bispecific antibody summit, September 27–28, 2011, Boston, MA | |
| Kim et al. | Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors | |
| JPWO2019165116A5 (https=) |